Samsung Medical Center
| Republik Korea | Türkei | Österreich | |
| Immuntherapie mit Keytruda (Pembolizumab) | von $5,200 | von $3,300 | von $15,000 |
| Hyperthermische intraperitoneale Chemotherapie (HIPEC) | von $23,500 | von $22,500 | von $40,000 |
| Chemotherapie bei Brustkrebs | von $19,200 | von $1,200 | von $15,000 |
| Blasenentfernung | von $18,500 | von $8,000 | von $22,000 |
| Strahlentherapie bei Darmkrebs | - | von $7,000 | von $12,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Blasenkrebs-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Blasenkrebs einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Blasenkrebs-Behandlungsreise nie allein.
Leiter der Abteilung für Urologie bei Samsung – Dr. Choi Han Yong ist auf die Behandlung von Blasenkrebs am Samsung Medical Center spezialisiert.
Dr. Son Dong Wan, MD, PhD, ist Leiter der Urologie am Naeun Hospital. Er ist spezialisiert auf urologische Onkologie, Harninkontinenz, sexuelle Funktionsstörungen und Laseroperationen an der Prostata. Er führt robotische und laparoskopische Operationen bei Krebserkrankungen der Prostata, Blase, Harnleiter und Niere durch. Zudem behandelt er die ureteropelvine Junktionsobstruktion (UPJ-Obstruktion).
Seine Promotion (PhD) erhielt er von der Pusan National University. Er absolvierte sein Internship und seine Residency am Pusan National University Hospital. Er war Chefarzt am Wallace Memorial Baptist Hospital und Professor am College of Medicine der Catholic University. Zudem war er Clinical Fellow am Seoul National University Bundang Hospital und Gastprofessor an der University of California, San Diego (UCSD). Eine Weiterbildung in Inkontinenzchirurgie absolvierte er an der Universität Lüttich.
Zu seinen Auszeichnungen zählen der Excellent Paper Award (2007) und der Academic Achievement Award (2014) der Korean Continence Society. Zudem erhielt er 2013 den Best Poster Award der European Association of Urology.
Dr. Won Sik Ham ist spezialisiert auf Urologie und Onkochirurgie am Severance Hospital.
Spezialist für laparoskopische und robotergestützte Operationen bei Blasenkrebs am Severance Hospital.
Robotic surgery is widely available for bladder cancer in South Korea. Leading medical centers in Seoul and Incheon utilize the da Vinci surgical system for complex oncology. These facilities maintain high standards with Joint Commission International and KOIHA accreditations for patient safety.
Bookimed Expert Insight: South Korea clinical volume provides a unique safety advantage for international patients. Severance Hospital alone treats over 4,000,000 patients annually and maintains a dedicated robotic surgery center. This massive scale allows surgeons like Dr. Koon Ho Rha to build experience levels that are rare even in Western tertiary centers. Patients should prioritize hospitals with over 30,000 annual operations to ensure they are treated by high-volume robotic teams.
South Korea offers systemic immunotherapies including Keytruda and Opdivo alongside cellular treatments like CAR-T and NK cell therapy. These protocols are available at JCI-accredited centers in Seoul. Specialists use these biologics for bladder, lung, and liver cancers to stimulate natural immune responses.
Bookimed Expert Insight: While many focus on drug costs, the real differentiator in Korea is digital integration. Centers like Seoul National University Bundang Hospital use the BESTcare system to sync genomic data with immunotherapy protocols. This reduces dosing errors and aligns treatment precisely with real-time patient blood markers.
Patient Consensus: Patients note the speed of starting treatment is impressive. Many emphasize that having a dedicated coordinator for translation makes navigating complex oncology schedules much easier.
Bladder replacement is a surgical procedure called neobladder reconstruction. While surgery is the primary curative approach for muscle-invasive cancer, non-surgical alternatives in Korea include drug-based immunotherapy with Keytruda. Other options include chemotherapy and Hyperthermic Intraperitoneal Chemotherapy to manage advanced cases without immediate removal.
Bookimed Expert Insight: Korea University Anam Hospital possesses notable expertise in Asian urological oncology and was among the first to perform robotic surgeries. Our data shows that while neobladder reconstruction is standard for invasive cases, centers like Samsung Medical Center utilize AI and advanced imaging to determine if bladder-sparing treatments are viable based on 2,000,000+ annual patient data points.
Patient Consensus: Patients note it is important to clarify if the treatment is curative or palliative. Many emphasize the relief of finding robotic options that prioritize faster recovery times.
Leading Korean hospitals for bladder cancer include Samsung Medical Center and Severance Hospital. These facilities specialize in robotic cystectomy and artificial bladder reconstruction. Many clinics hold JCI and KOIHA accreditations. They offer advanced therapies like HIPEC and immunotherapy to improve long-term survival for oncology patients.
Bookimed Expert Insight: Korea University Anam Hospital stands out for patients prioritizing technological firsts. While large centers like Samsung treat over 2,000,000 patients annually, Anam Hospital pioneered robotic bladder surgery in Asia. This concentration on robotic innovation often leads to more refined techniques for nerve-sparing and bloodless procedures.
International patients typically enter South Korea for bladder cancer treatment using the K-ETA electronic authorization or a standard C-3-9 medical visa. Short-term care under 90 days often requires only a tourist entry. Longer protocols like chemotherapy or immunotherapy may require a formal medical visa extension.
Bookimed Expert Insight: Korea University Anam Hospital performed Asia's first robotic bladder cancer surgery. Our data shows that while many patients enter on 90-day waivers, complex oncological cases often require transitioning to a C-3-M or G-1 medical visa. Major centers like Samsung Medical Center and Asan Medical Center maintain specialized teams to coordinate these legal transitions with the immigration office without interrupting your treatment schedule.
Patient Consensus: Patients note that standard tourist entries work well for initial consultations and diagnostics. For long-term chemotherapy, they emphasize getting a hospital invitation letter early to avoid visa extension delays.